As Pfizer and Moderna have tied off certain threads in their separate webs of mRNA patent litigation, Sanofi has opened a new ...

In Novo Nordisk and Eli Lilly’s competition to launch their respective GLP-1 obesity pills in the United States, the Danish ...

The clinical blueprint for Merck & Co.’s prized TROP2-directed antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), ...

Merck & Co.’s almighty Keytruda has become the first PD-1 inhibitor to show a benefit as a single agent for the front-line treatment of a subtype of endometrial cancer. | Merck & Co.’s almighty ...

Red-hot generative AI specialist Insilico Medicine has teamed up with another major biopharma player, this time linking up ...

After a 7% increase in revenue for the second quarter, which came on the heels of a 10% gain in Q1, Johnson & Johnson has bumped up its annual sales guidance. The company now projects 2026 revenue at ...

With a midstage peek at the data on Veradermics’ oral formulation of the molecule behind the ubiquitous hair regrowth ...

After speedrunning a series of major manufacturing milestones in the past year and a half, the “biotech floodgates” have ...

In an initiative to increase the efficiency of drug manufacturing in the United States, the FDA has proposed a streamlined pathway for registering production facilities that operate under a ...

Nearly a decade after spinning out its Chinese research hub to form Dizal Pharmaceutical, AstraZeneca is paying up to $1.5 billion to buy a piece of the pipeline, securing exclusive global rights for ...

Insulet’s wearable insulin patch Omnipod may be able to seamlessly control insulin delivery for patients with diabetes, but ...

Huyabio has scored a win in the largest oncology study it has undertaken in its 22 years, as its oral histone deacetylase ...